 |
|
Standard chemo works better against metastatic BRCA1/2 breast cancer than against sporadic tumors
April 17, 2008Berlin, Germany: The first study to investigate the effects of chemotherapy on metastatic breast cancer in women with the BRCA1 or BRCA2 gene mutation has shown that standard chemotherapy works better in these patients than in women without the BRCA1/2 mutation.
The authors of a study presented today (Thursday) at the 6th European Breast Cancer Conference (EBCC-6) in Berlin found that women with BRCA2-associated breast cancer had a significantly higher response rate, a longer time without the disease progressing, and a longer overall survival when treated with anthracycline-based regimens than did women with sporadic breast cancers that were not associated with BRCA1/2.
Women with BRCA1-associated breast cancer also did better than women with sporadic breast cancer, but the rates were not statistically significant.
Researchers at the Daniel den Hoed Cancer Centre/Erasmus Medical Centre (Rotterdam, The Netherlands) conducted the study. They matched 112 women with BRCA1-associated metastatic cancer and 29 women with BRCA2-associated metastatic cancer with 141 women with sporadic breast cancers. The women had been treated with anthracycline-based or taxane-based regimens, CMF (cyclophosphamide, methotrexate and fluorouracil 5FU) or other chemotherapy regimens.
BRCA2 women had a higher response rate to chemotherapy (89% versus 50%), a longer progression-free survival (nearly a third better) and a longer overall survival (47% better) than did women with sporadic cancers. When the researchers looked more closely at the type of chemotherapy the women had received, they found that the improved progression-free survival mainly occurred in patients on anthracyclines and disappeared for those treated with CMF.
The lead author of the study, Dr Mieke Kriege, an epidemiologist and project researcher at the Rotterdam Family Cancer Clinic, said: "It is difficult to make firm conclusions about response to different treatments from our results so far, but it does seem that the higher sensitivity to treatment by BRCA2-associated patients is especially caused by the anthracycline regimen."
The project leader, Professor Jan Klijn, medical oncologist and chairman of the Rotterdam Family Cancer Clinic, said: "Our findings show that various standard chemotherapy regimens are clinically effective in the treatment of metastatic BRCA1/2-associated breast cancer. The observation of the high efficacy of anthracycline-based regimens is especially reassuring. However, we would like to emphasise that larger, additional studies are urgently needed to investigate further newer regimens containing taxanes and platinum compounds."
Dr Kriege said: "Currently, there are very few studies on the efficacy of chemotherapy in BRCA1/2-associated breast cancer - mainly a few, very small studies with less than 44 patients in the neo-adjuvant setting. Our study is the only one in metastatic disease and, with 141 BRCA1/2 gene mutation carriers included, it is by far the largest study in the world."
The authors believe that an explanation of why chemotherapy seems to work better in BRCA1/2 breast cancers than in sporadic cancers is due to the lack of a working BRCA1/2 protein. "Functional BRCA1 and BRCA2 proteins are involved in DNA repair," said Dr Kriege. "Most chemotherapeutic agents are active by damaging DNA (especially anthracycline-based regimens). In BRCA1 and BRCA2 mutation carriers, who have no functional BRCA1 and BRCA2 proteins respectively, DNA repair after chemotherapy might be worse than in sporadic patients resulting in better treatment responses. Pre-clinical studies showed that BRCA1 and BRCA2 mutated cells are especially sensitive to chemotherapeutic agents that cause double-strand DNA breaks (such as anthracyclines and platinum)."
The researchers now plan to investigate the effects of adjuvant and neo-adjuvant treatments in women with BRCA1/2-associated breast cancers, and to evaluate taxane and platinum therapies further.
ECCO-the European CanCer Organisation
Researchers at the Daniel den Hoed Cancer Centre/Erasmus Medical Centre (Rotterdam, The Netherlands) conducted the study. They matched 112 women with BRCA1-associated metastatic cancer and 29 women with BRCA2-associated metastatic cancer with 141 women with sporadic breast cancers. The women had been treated with anthracycline-based or taxane-based regimens, CMF (cyclophosphamide, methotrexate and fluorouracil 5FU) or other chemotherapy regimens.
BRCA2 women had a higher response rate to chemotherapy (89% versus 50%), a longer progression-free survival (nearly a third better) and a longer overall survival (47% better) than did women with sporadic cancers. When the researchers looked more closely at the type of chemotherapy the women had received, they found that the improved progression-free survival mainly occurred in patients on anthracyclines and disappeared for those treated with CMF.
The lead author of the study, Dr Mieke Kriege, an epidemiologist and project researcher at the Rotterdam Family Cancer Clinic, said: "It is difficult to make firm conclusions about response to different treatments from our results so far, but it does seem that the higher sensitivity to treatment by BRCA2-associated patients is especially caused by the anthracycline regimen."
The project leader, Professor Jan Klijn, medical oncologist and chairman of the Rotterdam Family Cancer Clinic, said: "Our findings show that various standard chemotherapy regimens are clinically effective in the treatment of metastatic BRCA1/2-associated breast cancer. The observation of the high efficacy of anthracycline-based regimens is especially reassuring. However, we would like to emphasise that larger, additional studies are urgently needed to investigate further newer regimens containing taxanes and platinum compounds."
Dr Kriege said: "Currently, there are very few studies on the efficacy of chemotherapy in BRCA1/2-associated breast cancer - mainly a few, very small studies with less than 44 patients in the neo-adjuvant setting. Our study is the only one in metastatic disease and, with 141 BRCA1/2 gene mutation carriers included, it is by far the largest study in the world."
The authors believe that an explanation of why chemotherapy seems to work better in BRCA1/2 breast cancers than in sporadic cancers is due to the lack of a working BRCA1/2 protein. "Functional BRCA1 and BRCA2 proteins are involved in DNA repair," said Dr Kriege. "Most chemotherapeutic agents are active by damaging DNA (especially anthracycline-based regimens). In BRCA1 and BRCA2 mutation carriers, who have no functional BRCA1 and BRCA2 proteins respectively, DNA repair after chemotherapy might be worse than in sporadic patients resulting in better treatment responses. Pre-clinical studies showed that BRCA1 and BRCA2 mutated cells are especially sensitive to chemotherapeutic agents that cause double-strand DNA breaks (such as anthracyclines and platinum)."
The researchers now plan to investigate the effects of adjuvant and neo-adjuvant treatments in women with BRCA1/2-associated breast cancers, and to evaluate taxane and platinum therapies further.
ECCO-the European CanCer Organisation
Chemotherapy Current Events and Chemotherapy News RSSSensitive nanowire disease detectors made by Yale scientists
Yale scientists have created nanowire sensors coupled with simple microprocessor electronics that are both sensitive and specific enough to be used for point-of-care (POC) disease detection, according to a report in Nano Letters.
On the trail of a targeted therapy for blood cancers
nvestigators from the Herman B Wells Center for Pediatric Research at the Indiana University School of Medicine are focusing on a family of blood proteins that they hope holds a key to decreasing the toxic effects of chemotherapy in children and adults.
Hodgkin lymphoma -- new characteristics discovered
Researchers are still discovering new characteristics of Hodgkin lymphoma, a common form of cancer of the lymphatic system. The malignant cells are derived from white blood cells (B cells), but have lost a considerable part of the B cell-specific gene expression pattern.
Bisphenol A linked to chemotherapy resistance
Exposure to bisphenol A (BPA) may reduce the effectiveness of chemotherapy treatments, say University of Cincinnati (UC) scientists.
Pediatric study finds alternatives for radiation of low-grade brain tumors
A multi-institutional study led by researchers at The University of Texas M. D. Anderson Cancer Center has found that using chemotherapy alone and delaying or avoiding cranial radiation altogether can be effective in treating pediatric patients with unresectable or progressive low-grade glioma.
Mayo researchers explore issues related to multiple myeloma treatment
Multiple myeloma (MM) is a cancer of plasma cells that affects approximately 3 in 100,000 people each year. Although there is no cure for this disease, researchers have developed treatments that help relieve pain, control complications, and slow the progress of MM in many patients.
News from Cancer: Disparities in head and neck cancer patients
A new analysis finds considerable disparities in survival related to race and socio-economic status among patients with head and neck cancer.
Nanodiamond drug device could transform cancer treatment
A Northwestern University research team has developed a promising nanomaterial-based biomedical device that could be used to deliver chemotherapy drugs locally to sites where cancerous tumors have been surgically removed.
Children's National researchers develop novel anti-tumor vaccine
A novel anti-tumor vaccine for neuroblastoma and melanoma developed by scientists and clinicians at Children's National Medical Center in collaboration with investigators from the University of Iowa is showing significant impact on tumor growth in mice.
Surgical treatment provides new option for some colorectal cancer patients
Research out of Wake Forest University School of Medicine suggests that a surgical technique not traditionally used in advanced abdominal cancer may be a viable treatment option for some patients previously thought to be untreatable, offering the real possibility of extending survival for those patients.
More Chemotherapy Current Events and Chemotherapy News Articles
 | The Chemotherapy & Radiation Therapy Survival Guide (Chemotherapy and Radiation Therapy Survivor's Guide) by Judith McKay, Nancee Hirano |
 | Physician's Cancer Chemotherapy Drug Manual 2008 (Jones and Bartlett Series in Oncology) by Edward Chu, Vincent T. DeVita Jr. Completely revised and updated for 2008, this practical handbook is an up-to-date guide to all aspects of cancer chemotherapy. The book provides a comprehensive, easy to use catalogue of over 100 drugs-both on- and off-label-commonly used in cancer treatment. A section on Common Chemotherapy Regimens provides a quick reference to management of specific cancers, arranged... |
 | Chemotherapy Heals Cancer and the World is Flat by Lothar Hirneise In the future there will be two groups of cancer patients. Those who have read this book - and those who are uninformed. For many years Lothar Hirneise has been traveling throughout the world looking for the most successful cancer therapies, and he has been explaining to people that there is much more available than just chemotherapy and irradiation. Recognized internationally as Europe's leading... |
 | Chemotherapy and Radiation For Dummies by Alan P. Lyss, Humberto Fagundes, Patricia Corrigan An informative, compassionate guide for cancer patients and their loved ones Each year, more than 1 million people get treated for cancer, and most of these will undergo chemotherapy, radiation therapy, or both. This reassuring, optimistic guide helps people get a handle on treatment options and explains in plain English how chemotherapy and radiation therapy really work. It offers detailed... |
 | Questioning Chemotherapy by Ralph W. Moss A revealing critique of chemotherapy, this book looks objectively at chemo's successes and... |
 | Coping with Chemotherapy: Compassionate Advice and Authoritative Information from a Chemotherapy Survivor by Nancy Bruning After undergoing chemotherapy herself, author Nancy Bruning decided to write a candid and authoritative book to fill the void of information available for patients facing this procedure. In this completely revised, updated, and thoroughly researched edition, she details every step of the process, providing information even doctors neglect to tell their patients, including possible sexual and... |
 | 57 Good Things About Chemotherapy by Alec Kalla Rare humor that brings laughter to the halls of oncology, 57 Good Things About Chemotherapy provides precious relief from the stress and worry of cancer. Written by cancer survivor Alec Kalla and illustrated by Andy Williamson, this book makes cancer patients, survivors and caregivers smile, laugh and rid themselves of pentup emotional... |
 | Coping With Chemotherapy and Radiation Therapy by Daniel Cukier New advances in treatment offer cancer patients more options than ever before. Coping with Chemotherapy and Radiation is an accessible, accurate guide to the latest developments in radiation therapy and chemotherapy. You will find important information on how chemotherapy and radiation treatments work; what to expect from treatments, how to alleviate common side effects, and... |
 | Pocket Guide to Chemotherapy Protocols, Fourth Edition (Pocket Guide to Chemotherapy Protocols) by Edward Chu An indispensable quick reference for physicians, nurses, and other healthcare providers treating cancer patients! The updated Fourth Edition of the best-selling Pocket Guide to Chemotherapy Protocols is spiral bound and arranged alphabetically by cancer type for easy access, and contains combination as well as selected single-agent regimens for solid tumors and hematologic malignancies. In each... |
 | Chemotherapy and Biotherapy Guidelines and Recommendations for Practice (second edition) Order your copy of the newly revised and updated second edition of your #1 resource for chemotherapy administration! With more than 46,000 copies sold since 2001, you and thousands of your colleagues in oncology nursing have studied and consulted the information found in the first edition. The new second edition is based on current evidence and has been revised and updated to reflect the... |
| © 2008 BrightSurf.com |